GSM5359441
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.580
- INTERFERON_ALPHA_RESPONSE+0.570
- INTERFERON_GAMMA_RESPONSE+0.560
- INFLAMMATORY_RESPONSE+0.480
- COMPLEMENT+0.440
- IL6_JAK_STAT3_SIGNALING+0.440
- PANCREAS_BETA_CELLS+0.430
- COAGULATION+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- APOPTOSIS+0.380
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- G2M_CHECKPOINT-0.150
- WNT_BETA_CATENIN_SIGNALING-0.150
- MITOTIC_SPINDLE-0.020
- NOTCH_SIGNALING+0.000
- TGF_BETA_SIGNALING+0.010
- HYPOXIA+0.040
- UNFOLDED_PROTEIN_RESPONSE+0.060
- UV_RESPONSE_DN+0.060
- DNA_REPAIR+0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KEA474HN | low-grade glioma | — | 0.865 |
| 2 | BS_VARR255N | pilocytic astrocytoma | — | 0.864 |
| 3 | TCGA-BH-A0BC-01A-22R-A084-07 | — | A | 0.862 |
| 4 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.860 |
| 5 | MDT-AP-2149 | Med | Medulloblastoma | 0.857 |
| 6 | BS_9HSGV9TJ | pleomorphic xanthoastrocytoma(PXA) | — | 0.855 |
| 7 | TCGA-39-5022-01A-21R-1820-07 | — | cohortSQ1 | 0.854 |
| 8 | 2c10534e-5fb7-49b0-8f57-584cb31f3a08 | — | — | 0.854 |
| 9 | BS_1TPWFSK6 | subependymal giant cell astrocytoma(SEGA) | — | 0.854 |
| 10 | b428d434-2904-4f67-a66f-b7928e2951e3 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.330 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |